Sanofi - Aug 2, 2021 Form 3 Insider Report for Translate Bio, Inc. (TBIO)

Role
Other*
Signature
/s/ Alexandra Roger, as Head of Securities Law and Capital Markets of Sanofi
Stock symbol
TBIO
Transactions as of
Aug 2, 2021
Transactions value $
$0
Form type
3
Date filed
8/12/2021, 04:00 PM
Previous filing
Jul 28, 2021
Next filing
Sep 14, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding TBIO Common Stock 3.68M Aug 2, 2021 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Remarks:

In connection with an Agreement and Plan of Merger, dated as of August 2, 2021, by and among Sanofi, Vector Merger Sub, Inc., an indirect wholly owned subsidiary of Sanofi, and Translate Bio, Inc. (the "Issuer"), Sanofi entered into Tender and Support Agreements dated as of August 2, 2021 ("Tender and Support Agreements"), with certain stockholders of the Issuer (the "Supporting Stockholders"). As of August 2, 2021, the Reporting Person and the Supporting Stockholders collectively beneficially owned more than 10% of the outstanding shares of common stock of the Issuer. Neither the filing of this Form 3 nor any of its contents shall be deemed to constitute an admission by the Reporting Person that it is the beneficial owner of any shares beneficially owned by the Supporting Stockholders for purposes of Section 13(d) or Section 16 of the Exchange Act or for any other purpose, and the Reporting Person expressly disclaims beneficial ownership of such shares. The Reporting Person hereby disclaims that it is a member of a "group" (within the meaning of Section 13(d)(3) of the Exchange Act) with the Supporting Stockholders. Copies of the Tender and Support Agreements were filed as exhibits by the Issuer to its Form 8-K filed with the SEC on August 3, 2021.